Biotech & Pharma AlertsGet biotech and pharma industry news delivered straight to your inbox the moment it's released.
Developing effective vaccines against a deadly global pandemic is certainly bullish for a stock.
Indeed, Moderna and Pfizer shareholders have put away as much as 516% and 51% gains, respectively.
And when a lot of investors see this, they fear they’ve missed out.
Well, Michael’s here to assure you that you haven’t; not by a long shot.
And today, he’s got a vaccine stock you should put at the top of your “must-buy” list for the week ahead… .
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
If you are not paying attention to ARK Investments, you probably should be.
ARK invests in what they believe are disruptive innovations.
These are technologies and discoveries capable of changing the world and making a fortune for their investors.
Recently, an ARK fund bought shares of Surface Oncology (NASDAQ: SURF), a clinical-stage biotechnology company.
Should we jump on the bandwagon with this potentially explosive stock? Sadly, the answer is probably not.
We'll show you exactly why, including how to find stocks actually worth your money…
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
The anticipation is palpable… and building fast. We've had three reports on extremely effective upcoming coronavirus vaccines, and each report practically blows the last one out of the water.
First we heard preliminary reports that Pfizer and BioNTech's revolutionary messenger RNA (mRNA) coronavirus vaccine was 90% effective. That was great… until yesterday morning, when the biotechs got back in touch to say the real figure was something closer to 95%. And in the middle, we've heard from Moderna, which is reporting its mRNA vaccine is 94.5% effective.
Every time, stocks have taken off like a shot at the news; vaccines have helped push the Dow back above its February 2020 highs.
Here's the thing… setting aside the six vaccines The New York Times reports are in limited use in China and Russia – about which there are many unanswered questions – there are at least nine more coronavirus vaccines deep in phase 3, large-scale efficacy trials.
And there are no less than 55 more candidates in earlier, phase 1 and 2 trials. Some of these vaccine candidates won't advance, but others almost certainly will – two have already.
That all this has happened in less than a year is an "Apollo moonshot"-like scientific achievement. But that's also a whole lot of concentrated upside potential that could flood the markets and push stocks to almost unthinkable highs.
So I asked Money Morning Chief Investment Strategist Shah Gilani what it all means for us investors…
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Pfizer's recent news that their COVID-19 vaccine is 90% effective sent the market (and Pfizer's stock) soaring.
And while those who had already invested in the stock have made a nice return, Tom's going to show you the quick and easy way to almost quadruple your money on it…
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
Not every biotech company is doing well in the search for an effective COVID-19 vaccine or treatment.
And the latest firm to struggle is Eli Lilly, whose antibody clinical trial was paused due to failure to show any real results.
So today, Andrew's going to show you a much more profitable move to make instead of chasing every vaccine "breakthrough" news…
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
One perfectly positioned biotech Don’s going to tell you about today is close to hitting the crucial $1 billion threshold.
It hasn’t happened yet, but when it does, they’ll have done it faster than the likes of Apple or Google.
And if you’re finding out about it now, you’re just in time because the setup looks very promising.
But you’ll have to act fast, and grab the shares before Wall Street finds out about it….
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
One of the starkest lessons of the global novel coronavirus pandemic is the need for medicine to start looking at existing drugs and procedures in a new way.
We've already seen the benefits of such an approach. The discovery that remdesivir and dexamethasone – an antiviral and a steroid – could both help save severely ill COVID-19 patients' lives springs right to mind.
But adapting the old to fight the new isn't just limited to drugs. Existing medical technology ("medtech") is being used in entirely new ways, or in situations that would've been unthinkable just 10 or 12 months ago.
That's why today I want to talk to you about two compelling companies behind a radical, aggressive therapy that can deliver a "one-two punch" for coronavirus patients who might've otherwise died… Full Story
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
It might be too early to call it "a light at the end of the tunnel," but the quest for a novel coronavirus vaccine has entered a new, perhaps decisive phase.
We knew fairly quickly after the pandemic exploded that life in most places could never be as it was until an effective vaccine or therapy was produced.
And now we're beginning to get a picture – tentative, to be sure – of when and how that might happen.
Infectious disease expert Dr. Anthony Fauci has said he expects FDA emergency approval of some kind of vaccine by November or December of this year.
Taking it a step further, both Bill Gates and CDC Director Dr. Robert Redfield have indicated the logistics of vaccine distribution will mean life "will start to return to normal" by second and third quarters of 2021, or roughly 18 months after the social and economic devastation of this crisis started.
That seems like an awfully long time, and of course it is, but, as of now, the current "speed record" holder in the vaccine stakes belongs to Merck & Co. Inc.'s Mumpsvax.
And when I say "speed record," understand that it took nearly five years to develop Mumpsvax back in the 1960s.
For us to have an effective vaccine – any vaccine – by the end of 2020, or a little over a year since the disease emerged, would be a breathtaking, unparalleled scientific achievement.
There are dozens upon dozens of different vaccines and therapies being researched all over the world, all in different stages. The market, however, is paying the closest attention to just a few.
Aside from AstraZeneca Plc. in the United Kingdom, there are two frontrunner candidates in the United States, both in late, phase 3 clinical trials.
There's Moderna Inc., whose shares have soared as high as 400%, and Pfizer Inc., which has been rather more subdued this year, but whose vaccine candidate is a favorite in some circles for the first emergency approval.
With that said, the stock I'm going to name might not be first, but it may very well be the best… Full Story
With that said, the stock I'm going to name might not be first, but it may very well be the best...
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
2020 has not been the most exciting year for IPOs.
While the big coronavirus crash in March prompted a lot of investors to buy stocks on the cheap,.
the uncertainty has kept many companies from going public with their shares.
Of course, for every rule there are exceptions.
Biotech IPOs have been as popular as ever amid the pandemic, and for good reason too: There’s money out there for companies who can help end the pandemic.
Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
"Lead, follow, or get out of the way."
This is one of those well-known aphorisms that's been around forever – though its originator is unknown.
Truth be told, it doesn't matter who said it first. It's a great bit of advice.
Especially as we interpret it.
In our investment work here at Money Morning, we always seek to lead Wall Street and the rest of the packrat investment crowd.
We never follow, especially since "the crowd" tends to be indecisive, late to the gun – or flat out wrong.
And we always get out of the way – sidestepping the dust-rising thump that's an inevitable result of the miscues and sins of the Wall Street Goliath.
It's a simple formula. And a successful one.
And it's the reason we keep outperforming "the crowd."
Like the 2,067% gain on biotech Galapagos NV, the very first stock I recommended on the very first day I published my Member-based service, Private Briefing, back in August 2011.
My readers also pulled down peak gains of more than 2,892% in Nvidia, 2,828% in Advanced Micro Devices, 818% in biotech buyout Pharmacyclics, and more.
Today, I've decided to share my latest insight on one of my big biotech winners with Money Morning readers because the opportunity is too good to keep to ourselves. And since my colleague Michael Robinson recently talked about 2020's record-crushing biotech IPOs, it's the perfect time to share this.
The company I'm showing you today is essential to biotech stocks. It's a "biotech-enabler" that's zoomed 1,755% since I first told my readers about it back in June 2013.
In 2013, it was trading at $8.14.
It closed July 30 at $151.25 – not long after Investor's Business Daily said the stock had entered a "Buy Zone."
True, but where were they seven years and 1,755% ago?
Of course, what's important now is what comes next – and it's clear this stock's run isn't over… Full Story
Start the conversation